Addus HomeCare (ADUS) Earnings Date & Reports

Key Takeaways

• Addus HomeCare (ADUS) is scheduled to report second-quarter 2026 earnings on Monday, August 3, 2026, after the market close, with a conference call to follow on Tuesday, August 4.
• Wall Street consensus estimates point to earnings per share (EPS) of approximately $1.69, up from $1.49 in the same quarter a year ago, and revenue of roughly $376 million.
• The company has beaten EPS estimates in seven of the last eight quarters, reinforcing a pattern of consistent bottom-line outperformance.
• Investor focus will center on same-store growth trends across Personal Care and Hospice segments, as well as any updates on the M&A (mergers and acquisitions) pipeline.
• A new Medicare moratorium on home health and hospice provider enrollment, combined with recent index removals from Russell growth benchmarks, adds complexity to the near-term outlook.

Earnings Context and Why It Matters

Addus HomeCare, a provider of in-home personal care, hospice, and home health services operating across 24 states, enters its second-quarter report at a pivotal moment. The aging U.S. population continues to drive structural demand for home-based care, and Addus has capitalized on this trend through both organic growth and strategic acquisitions. However, the regulatory landscape is shifting. A newly imposed Medicare moratorium on new home health and hospice provider enrollments introduces uncertainty around future expansion opportunities. Meanwhile, the company's recent removal from several Russell growth indices has weighed on investor sentiment, even as fundamentals remain solid. With the stock trading near $119 — well below its 52-week high of $124.44 and closer to the midpoint of its annual range — this earnings report will test whether operational strength can offset external headwinds.

Earnings Expectations

Analysts expect Addus HomeCare to deliver Q2 2026 EPS of approximately $1.69, according to consensus data compiled by TipRanks from 12 analysts. This would represent roughly 13% growth compared to the $1.49 reported in the second quarter of 2025. Revenue is projected to reach about $376 million, up approximately 8% year-over-year from $349.4 million in the prior-year period.

The company's track record supports cautious optimism on the earnings front. In Q1 2026, Addus posted adjusted EPS of $1.62, beating consensus estimates of $1.55 by 4.5%, while revenue of $363.5 million modestly missed the $366.4 million consensus. This pattern — EPS beats with occasional revenue shortfalls — has characterized several recent quarters and reflects disciplined cost management alongside variable top-line dynamics.

Key metrics to watch include same-store Personal Care revenue growth (6.5% in Q1), same-store hours growth (2.2% in Q1), Hospice average daily census (ADC), which stood at 3,804 in Q1, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin, which management expects to remain above 12% for the full year. The company's Home Health segment, though small at 4.6% of revenue, will also be scrutinized for signs of a turnaround after experiencing organic revenue declines.

AI Screener

For investors seeking to identify stocks with earnings momentum or technical breakout potential ahead of key events like quarterly reports, Tickeron's AI Screener offers a powerful solution. This AI-driven discovery tool enables traders and investors to filter thousands of stocks and ETFs using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and proprietary AI-generated signals. Rather than manually scanning charts and financial statements, users can surface trade ideas, trending stocks, and breakout candidates across sectors in a fraction of the time. Whether tracking home care providers like Addus HomeCare or searching for opportunities in other healthcare sub-industries, the AI Screener helps streamline the research process and uncover actionable market opportunities.

Market Reaction and Investor Sentiment

Investor sentiment heading into the Q2 report is mixed. ADUS shares have recovered from a post-Q1 earnings dip that briefly pushed the stock toward $97 in early May, but the stock has not reclaimed levels near $124 seen earlier in 2026. The company's removal from the Russell 2000 Growth, Russell 2500 Growth, and related benchmarks in late June triggered additional selling pressure from passive funds tracking those indices.

Analyst ratings reflect a similar split. The consensus remains a Moderate Buy, with firms such as Oppenheimer ($155 target), Stephens ($135), and TD Cowen ($131) maintaining constructive outlooks. However, Barclays has held an Underweight rating and recently raised its target only modestly to $96, citing the Medicare moratorium's potential to limit acquisition-driven growth. Short interest in ADUS has risen, with approximately 1.25 million shares sold short as of mid-July — equivalent to roughly five days of average trading volume — suggesting increased bearish positioning ahead of the report.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, the forward-looking commentary from Chairman and CEO Dirk Allison and CFO Brian Poff will be critical in shaping the post-earnings narrative.

M&A Strategy Under the Moratorium. Addus has historically used acquisitions to enter new states and deepen its footprint in existing markets — the recent HomeCourt deal in Indiana being a case in point. The Medicare moratorium on new provider enrollments may temporarily slow deal-making in the Hospice and Home Health segments. Investors will listen closely for management's assessment of how long the moratorium could last and whether the company can pivot its M&A focus toward Personal Care assets, which fall under state-level Medicaid (a joint federal-state health program for low-income individuals) oversight rather than Medicare (the federal health insurance program primarily for seniors).

Caregiver Hiring and Retention. Labor availability remains a defining challenge in the home care industry. Addus reported an improved hiring rate of 108 caregivers per day in Q1, up from 103 per day in Q4 2025. Sustaining or improving this trend is essential to converting authorized care hours into billable revenue. The company's Addus Connect mobile app, designed to improve caregiver engagement and scheduling efficiency, will be an area of interest as adoption expands beyond initial states.

Medicaid Rate Environment. With Personal Care representing over 77% of revenue and predominantly funded through state Medicaid programs, any shifts in state-level reimbursement rates carry meaningful implications. While no major rate disruptions have surfaced, the ongoing state budget cycles will be worth monitoring for any signs of tightening.

Balance Sheet Flexibility. Addus ended Q1 with approximately $103 million in cash and $94.3 million in bank debt, with significant revolver capacity of roughly $548 million available. This conservative capital position provides a cushion against uncertainty and positions the company to act quickly when acquisition opportunities reopen. Any updates on capital allocation priorities — including potential share repurchases — will be relevant for investors evaluating total return prospects.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations